ClinicalTrials.gg
RecruitingNCT06871774Updated Jun 25, 2026

Comparison of Single vs. Dual Perclose Devices for Large-Bore Access Closure in TAVR

An interventional study of Single Perclose Pro vascular closure device and Dual Perclose vascular closure device in Transcatheter Aortic Valve Replacement, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Aortic Valve Disease with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Aortic Valve Disease · United States.

Planned enrollment
13th of 31
300 · median 190
Started
2025
with 2 others
No phase
27 of 47
9 open now
Primary completion
2027-06
later than 15 of 22 live
Registered
44th of 47
by date

Among the 47 studies in Aortic Valve Disease with a site in United States, this one is the 13th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2025, is one of 27 with no phase, reaches primary completion later than 15 of the 22 other live ones, and was the 44th registered.

Aortic Valve Disease

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

12 of the 47 studies in Aortic Valve Disease with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Aortic Valve Disease with a site in United States, or all of them as a file.
02

Study summary

This study will compare the use of one Perclose device to the usual approach of two devices for pre-closure during Transcatheter Aortic Valve Replacement (TAVR). The study will compare the time it takes for bleeding to stop using the different closure approaches. The study will also compare complications when using one Perclose device versus two.

Read the detailed description

This single-center randomized trial compares single versus dual Perclose devices for pre-closure of vascular access for Transcatheter Aortic Valve Replacement (TAVR) and investigation will evaluate the efficacy and performance of these two pre-closure approaches. The study will provide valuable insights into optimizing pre-closure techniques, potentially enhancing patient outcomes and reducing complications associated with Transcatheter Aortic Valve Replacement (TAVR) procedures. The trial will aim to enroll patients undergoing TAVR, with an an equal number of patients randomized to each pre-closure strategy arm.

03

Conditions studied

  • Transcatheter Aortic Valve Replacement

Browse trials for

Keywords

  • aortic valve diseases
  • Perclose device
  • arteriotomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient age 18 or older
  • Transfemoral transcatheter aortic valve replacement (TAVR)
  • Implantation of CoreValve replacement valve
  • Access using 14 French sheaths
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Alternative Access Routes: Patients undergoing transcatheter aortic valve replacement (TAVR) via alternative access routes such as subclavian access or transapical access.
  • Planned Surgical Cut-Down: Patients planned for surgical cut-down procedures rather than percutaneous access.
  • Vascular Access Complications: Patients with known vascular complications at the femoral access site, such as residual hematoma, recent femoral arteriotomy or venotomy within the past 10 days, history of significant vascular complications or prior intravascular closure device use within the previous 30 days.
  • Arterial or Venous Issues: Patients with small femoral arteries or veins (\<5 mm in diameter), patients with access sites located in vascular grafts.
  • Body Composition: Patients with >35
  • Cardiac Vasculature: Patients with excess calcification of vessels as determined by echocardiography and/or CT angiography
  • Infection or Inflammation: Active systemic or cutaneous infection or inflammation in the vicinity of the groin.
  • Coagulation and Hematological Disorders: Known history of bleeding diathesis, coagulopathy, hypercoagulability, or count \<100,000 cells/mm³. Pre-existing immunodeficiency disorder or chronic use of high-dose systemic .
  • Severe Morbidity: Severe co-existing morbidities with a less than 12 months.
  • Mobility Issues: Patients unable to routinely walk at least 20 feet without assistance.
  • Recent Anticoagulation: Use of low molecular weight heparin (LMWH) within 8 hours before or after the procedure.
  • Pregnancy and Lactation: Pregnant or lactating women.
  • Incompatible Procedure Plan: Patients receiving the Edwards Sapien valve (Edwards Lifesciences, Irvine, CA)
  • : Patients with contraindications for the use of Perclose device.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Single Device

    A single Perclose device will be used for pre-closure of the vascular access site, with manual pressure and up to two additional devices used as needed to achieve hemostasis.

    Device: Single Perclose Pro vascular closure device

  • Active comparator
    Two device

    Two Perclose devices will be used for pre-closure of the vascular access site, with manual pressure and an additional device used as needed to achieve hemostasis.

    Device: Dual Perclose vascular closure device

Interventions

  • DeviceSingle Perclose Pro vascular closure device

    Use of a single Perclose device for pre-closure of vascular access site after removal of TAVR sheath.

  • DeviceDual Perclose vascular closure device

    Use of two Perclose devices for pre-closure of vascular access site after removal of TAVR sheath.

06

What researchers measure

Primary outcomes

  1. Number of Patients With Vascular Complications

    Number of subjects in each group experiencing major or minor vascular complications directly related to the TAVR procedure occurring during the index hospitalization.

    Time frame: Day 5 post-procedure

  2. Number of Patients With Life-threatening bleeding

    Number of subjects in each group experiencing any bleeding event related to the TAVR procedure that is life-threatening within 24 hours post-procedure.

    Time frame: Hour 24 post-procedure

  3. Number of Patients With Major or Minor Bleeding Complications Without Life-Threatening Condition

    Number of subjects in each group experiencing bleeding complications related to the TAVR procedure that do not meet the criteria for life-threatening bleeding but still result in significant clinical concern within 24 hours of the index procedure.

    Time frame: Hour 24 post-procedure

  4. Time to Hemostasis

    For each subject, time elapsed from initial deployment of the initial one or two Perclose devices (depending on assigned group) to complete hemostasis of the femoral access site. Measured in seconds.

    Time frame: 1 hour post procedure

Secondary outcomes

  1. Additional Closure Device Use

    Number of subjects requiring use of additional closure devices beyond the initial closure strategy required to achieve hemostasis at the femoral access site within 24 hours post-procedure. The number and type of devices will be recorded for each subject.

    Time frame: Hour 24 post-procedure

  2. In-Hospital Serious Vascular Complications Requiring Percutaneous or Surgical Interventions

    Number of subjects in each group experiencing severe vascular complications that necessitate either percutaneous procedures or surgical interventions during the index hospitalization.

    Time frame: Day 5 post-procedure

  3. Number of Patients With Limb Ischemia Related to TAVR During Index Admission

    Number of subjects in each group experiencing significant peripheral ischemia related to the arteriotomy closure between the TAVR procedure and discharge.

    Time frame: Day 5 post-procedure

  4. Limb Ischemia Related to TAVR

    Number of subjects in each group experiencing significant peripheral ischemia related to the arteriotomy closure monitored within 30 days post procedure.

    Time frame: Day 30 post-procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 61 interventional studies with no phase under Aortic Valve Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 61. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 12, 2025
StartActual
Jun 16, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06871774
Responsible party
Sponsor
First posted
Mar 12, 2025
Start date
Jun 16, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Suhail Q Allaqaband, MD
Contact
suhail.allaqaband@aah.org
414-649-3491
Suhail Q Allaqaband, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion